Inotiv (LTS:0HN9) 3-Year Book Growth Rate : 147.30% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Inotiv 3-Year Book Growth Rate?

Inotiv's Book Value per Share for the quarter that ended in Mar. 2024 was $8.04.

During the past 12 months, Inotiv's average Book Value per Share Growth Rate was -24.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was 147.30% per year. During the past 5 years, the average Book Value per Share Growth Rate was 85.30% per year. During the past 10 years, the average Book Value per Share Growth Rate was 27.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Inotiv was 147.30% per year. The lowest was -29.80% per year. And the median was -2.60% per year.

Competitive Comparison of Inotiv's 3-Year Book Growth Rate

For the Diagnostics & Research subindustry, Inotiv's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inotiv's 3-Year Book Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Inotiv's 3-Year Book Growth Rate falls into.

Inotiv 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Inotiv (LTS:0HN9) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Inotiv 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Inotiv's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv (LTS:0HN9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (LTS:0HN9) » Definitions » 3-Year Book Growth Rate

Comparable Companies

ENZ VNRX BIOQ STIM OCX PSNL PRE XGN SLDX BIAF TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

NOTV:USA BS50:Germany BS50:Germany

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (LTS:0HN9) Headlines

No Headlines